Crizotinib (Xalkori▼): risk of cardiac failure
There have been reports of severe, sometimes fatal, cases of cardiac failure in patients treated with crizotinib.
Vemurafenib (Zelboraf▼): risk of potentiation of radiation toxicity
Prescribers should be aware of the risk of potentiation of radiation toxicity with vemurafenib when given before, during, or after radiotherapy.
Letters sent to healthcare professionals in October 2015
In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenib.